Boron neutron capture therapy: Current status and future perspectives

被引：173

作者：

Dymova, Mayya Alexandrovna ^{[1
]}

Taskaev, Sergey Yurjevich ^{[2
,3
]}

Richter, Vladimir Alexandrovich ^{[1
]}

Kuligina, Elena Vladimirovna ^{[1
]}

机构：

[1] Russian Acad Sci, Inst Chem Biol & Fundamental Med, Lab Biotechnol, Siberian Branch, Lavrentjeva Av 8, Novosibirsk 630090, Russia

[2] Russian Acad Sci, Budker Inst Nucl Phys, Siberian Branch, Lavrentjeva Av 11, Novosibirsk 630090, Russia

[3] Novosibirsk State Univ, Lab Boron Neutron Capture Therapy, Pirogova Str 1, Novosibirsk 630090, Russia

来源：

CANCER COMMUNICATIONS | 2020年 / 40卷 / 09期

基金：

俄罗斯科学基金会;

关键词：

boron compounds; Boron neutron capture therapy; cancer treatment; cancer; drug delivery; SQUAMOUS-CELL CARCINOMA; MALIGNANT PLEURAL MESOTHELIOMA; BLOOD-BRAIN-BARRIER; RECURRENT HEAD; EPITHERMAL NEUTRON; CLINICAL-TRIAL; NECK-CANCER; DNA-DAMAGE; IN-VITRO; BNCT;

D O I：

10.1002/cac2.12089

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The development of new accelerators has given a new impetus to the development of new drugs and treatment technologies using boron neutron capture therapy (BNCT). We analyzed the current status and future directions of BNCT for cancer treatment, as well as the main issues related to its introduction. This review highlights the principles of BNCT and the key milestones in its development: new boron delivery drugs and different types of charged particle accelerators are described; several important aspects of BNCT implementation are discussed. BCNT could be used alone or in combination with chemotherapy and radiotherapy, and it is evaluated in light of the outlined issues. For the speedy implementation of BCNT in medical practice, it is necessary to develop more selective boron delivery agents and to generate an epithermal neutron beam with definite characteristics. Pharmacological companies and research laboratories should have access to accelerators for large-scale screening of new, more specific boron delivery agents.

引用

页码：406 / 421

页数：16

共 132 条

[1] BNCT for advanced or recurrent head and neck cancer
Aihara, Teruhito
Morita, Norimasa
Kamitani, Nobuhiko
Kumada, Hiroaki
Ono, Koji
Hiratsuka, Junichi
Harada, Tamotsu
[J]. APPLIED RADIATION AND ISOTOPES, 2014, 88 : 12 - 15
[2] An innovative therapeutic approach for malignant mesothelioma treatment based on the use of Gd/boron multimodal probes for MRI guided BNCT
Alberti, Diego
Deagostino, Annamaria
Toppino, Antonio
Protti, Nicoletta
Bortolussi, Silva
Altieri, Saverio
Aime, Silvio
Crich, Simonetta Geninatti
[J]. JOURNAL OF CONTROLLED RELEASE, 2018, 280 : 31 - 38
[3] alikan B., 2018, Ionizing Radiation Effects and Applications, P135, DOI [10.5772/intechopen.74691, DOI 10.5772/INTECHOPEN.74691]
[4] [Anonymous], 2016, Science, V351, DOI 10.1126/science.aaf5401
[5] [Anonymous], 2001, CURRENT STATUS NEUTR
[6] Cell death following BNCT: A theoretical approach based on Monte Carlo simulations
Ballarini, F.
Bakeine, J.
Bortolussi, S.
Bruschi, P.
Cansolino, L.
Clerici, A. M.
Ferrari, C.
Protti, N.
Stella, S.
Zonta, A.
Zonta, C.
Altieri, S.
[J]. APPLIED RADIATION AND ISOTOPES, 2011, 69 (12) : 1745 - 1747
[7] Blood-brain barrier transport machineries and targeted therapy of brain diseases
Barar, Jaleh
Rafi, Mohammad A.
Pourseif, Mohammad M.
Omidi, Yadollah
[J]. BIOIMPACTS, 2016, 6 (04) : 225 - 248
[8] Boron delivery agents for neutron capture therapy of cancer
Barth, Rolf F.
Mi, Peng
Yang, Weilian
[J]. CANCER COMMUNICATIONS, 2018, 38 : 1 - 15
[9] A realistic appraisal of boron neutron capture therapy as a cancer treatment modality
Barth, Rolf F.
Zhang, Zizhu
Liu, Tong
[J]. CANCER COMMUNICATIONS, 2018, 38
[10] Evaluation of TK1 targeting carboranyl thymidine analogs as potential delivery agents for neutron capture therapy of brain tumors
Barth, Rolf F.
Yang, Weilian
Nakkula, Robin J.
Byun, Youngjoo
Tjarks, Werner
Wu, Lai Chu
Binns, Peter J.
Riley, Kent J.
[J]. APPLIED RADIATION AND ISOTOPES, 2015, 106 : 251 - 255

← 1 2 3 4 5 6 7 8 9 10 →